{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:47:56Z","timestamp":1793778476063,"version":"4.6.1"},"reference-count":146,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["- 2020R1I1A3074575"],"award-info":[{"award-number":["- 2020R1I1A3074575"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2026.102859","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:27:47Z","timestamp":1770312467000},"page":"102859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-239X","authenticated-orcid":false,"given":"Chiranjib","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindasamy","family":"Agoramoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102859_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40291-024-00696-z","article-title":"Exagamglogene Autotemcel: First Approval","volume":"28","author":"Hoy","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib2","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.944204","article-title":"Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent beta-Thalassemia","volume":"30","author":"Parums","year":"2024","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.omtn.2026.102859_bib3","first-page":"280","article-title":"Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy","volume":"331","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2026.102859_bib4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.102859_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2018.04.001","article-title":"CRISPR\/Cas9 for cancer research and therapy","volume":"55","author":"Zhan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omtn.2026.102859_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/cvr\/cvz250","article-title":"CRISPR\/Cas9 gene-editing strategies in cardiovascular cells","volume":"116","author":"Vermersch","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2026.102859_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102859_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrn.2015.2","article-title":"Applications of CRISPR-Cas systems in neuroscience","volume":"17","author":"Heidenreich","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtn.2026.102859_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","article-title":"CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases","volume":"29","author":"Sharma","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib11","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/jcp.30064","article-title":"CRISPR\/Cas gene therapy","volume":"236","author":"Zhang","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.omtn.2026.102859_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","article-title":"What is CRISPR\/Cas9?","volume":"101","author":"Redman","year":"2016","journal-title":"Arch. Dis. Child. Educ. Pract. Ed."},{"key":"10.1016\/j.omtn.2026.102859_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.699597","article-title":"The Potential of CRISPR\/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases","volume":"9","author":"Abdelnour","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2026.102859_bib14","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2174\/1389450117666160527142321","article-title":"The Smart Programmable CRISPR Technology: A Next Generation Genome Editing Tool for Investigators","volume":"18","author":"Chakraborty","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.omtn.2026.102859_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s42003-024-06121-9","article-title":"Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs","volume":"7","author":"Baylot","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtn.2026.102859_bib16","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.omtn.2026.102859_bib17","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1056\/NEJMp2314279","article-title":"Welcoming the Era of Gene Editing in Medicine","volume":"390","author":"Daley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib18","first-page":"205","article-title":"Genome Editing in Medicine: Tools and Challenges","volume":"28","author":"Petraityte","year":"2021","journal-title":"Acta Med. Litu."},{"key":"10.1016\/j.omtn.2026.102859_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002071","article-title":"In the business of base editors: Evolution from bench to bedside","volume":"21","author":"Porto","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omtn.2026.102859_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2310\/JIM.0b013e3182160d70","article-title":"The path from bench to bedside: considerations before starting the journey","volume":"59","author":"Freeman","year":"2011","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib21","series-title":"Biomarkers. Principles of Translational Science in Medicine","first-page":"135","author":"Wehling","year":"2021"},{"key":"10.1016\/j.omtn.2026.102859_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","article-title":"The next generation of evidence-based medicine","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib23","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ymthe.2021.09.027","article-title":"CRISPR-derived genome editing therapies: Progress from bench to bedside","volume":"29","author":"Rees","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib24","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/jcmm.14916","article-title":"CRISPR\/Cas9-mediated genome editing: From basic research to translational medicine","volume":"24","author":"Jacinto","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib25","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA Base-Editing and Prime-Editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.102859_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7676","article-title":"Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing","volume":"8","author":"Park","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.102859_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0044-1785234","article-title":"CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications","volume":"11","author":"Kolanu","year":"2024","journal-title":"Glob. Med. Genet."},{"key":"10.1016\/j.omtn.2026.102859_bib28","article-title":"Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering. Molecular therapy","volume":"4","author":"Zhang","year":"2015","journal-title":"Nucleic acids"},{"key":"10.1016\/j.omtn.2026.102859_bib29","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1039\/D2SC07067G","article-title":"Minimizing the off-target frequency of the CRISPR\/Cas9 system via zwitterionic polymer conjugation and peptide fusion","volume":"14","author":"Han","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.omtn.2026.102859_bib30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing Technologies for Gene and Cell Therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.omtn.2019.02.027","article-title":"Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application","volume":"16","author":"Khan","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102859_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2026.102859_bib33","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1172\/JCI72992","article-title":"Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9","volume":"124","author":"Gupta","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102859_bib34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1365-2958.1993.tb00976.x","article-title":"Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method","volume":"10","author":"Groenen","year":"1993","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.omtn.2026.102859_bib35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3201\/eid0502.990210","article-title":"Rapid molecular genetic subtyping of serotype M1 group A Streptococcus strains","volume":"5","author":"Hoe","year":"1999","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.omtn.2026.102859_bib36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00253-019-10314-2","article-title":"Haloferax volcanii for biotechnology applications: challenges, current state and perspectives","volume":"104","author":"Haque","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102859_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0167-4781(96)00040-1","article-title":"Long tandemly repeated repetitive (LTRR) sequences in the filamentous cyanobacterium Anabaena sp. PCC 7120","volume":"1307","author":"Masepohl","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2026.102859_bib38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2958.1993.tb01721.x","article-title":"Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites","volume":"9","author":"Mojica","year":"1993","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.omtn.2026.102859_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-2958.2000.01838.x","article-title":"Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria","volume":"36","author":"Mojica","year":"2000","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.omtn.2026.102859_bib40","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.omtn.2026.102859_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00580-17","article-title":"History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology","volume":"200","author":"Ishino","year":"2018","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.omtn.2026.102859_bib42","doi-asserted-by":"crossref","first-page":"19012","DOI":"10.1073\/pnas.1318481110","article-title":"Optimized gene editing technology for Drosophila melanogaster using germ line-specific Cas9","volume":"110","author":"Ren","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102859_bib43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1534\/genetics.113.156737","article-title":"Highly improved gene targeting by germline-specific Cas9 expression in Drosophila","volume":"195","author":"Kondo","year":"2013","journal-title":"Genetics"},{"key":"10.1016\/j.omtn.2026.102859_bib44","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.celrep.2014.03.017","article-title":"Highly Efficient Targeted Mutagenesis of Drosophila with the CRISPR\/Cas9 System","volume":"6","author":"Bassett","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.102859_bib45","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"Wang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102859_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.stem.2013.10.016","article-title":"Correction of a genetic disease in mouse via use of CRISPR-Cas9","volume":"13","author":"Wu","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2026.102859_bib47","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2026.102859_bib48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature.2016.20988","article-title":"CRISPR gene-editing tested in a person for the first time","volume":"539","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102859_bib49","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib50","series-title":"Hematopoietic Stem Cell Transplantation. StatPearls","author":"Khaddour","year":"2024"},{"key":"10.1016\/j.omtn.2026.102859_bib51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/bmj.321.7269.1117","article-title":"Single gene disorders or complex traits: lessons from the thalassaemias and other monogenic diseases","volume":"321","author":"Weatherall","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.omtn.2026.102859_bib52","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1093\/hmg\/ddl060","article-title":"Lessons from studying monogenic disease for common disease","volume":"15","author":"Peltonen","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.102859_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102859_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-022-01237-z","article-title":"Advances in the diagnosis and treatment of sickle cell disease","volume":"15","author":"Brandow","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtn.2026.102859_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/9781119252863.ch14","article-title":"Hemoglobinopathies due to structural mutations","volume":"108","author":"Layton","year":"2019","journal-title":"Molecular Hematology"},{"key":"10.1016\/j.omtn.2026.102859_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment","volume":"5","author":"Inusa","year":"2019","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.omtn.2026.102859_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10101608","article-title":"The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications","volume":"10","author":"Wang","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.omtn.2026.102859_bib58","first-page":"443","article-title":"Sickle cell anemia, a molecular disease","volume":"109","author":"Pauling","year":"1949","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.102859_bib59","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/9780470987001.ch10","article-title":"Sickle cell disease","author":"McMahon","year":"2006","journal-title":"Pediatric Hematology"},{"key":"10.1016\/j.omtn.2026.102859_bib61","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.102859_bib62","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bcmd.2010.05.006","article-title":"Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus","volume":"45","author":"Jawaid","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.omtn.2026.102859_bib63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1749-6632.2010.05574.x","article-title":"Transcriptional silencing of fetal hemoglobin by BCL11A","volume":"1202","author":"Sankaran","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.omtn.2026.102859_bib64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-031-62731-6_9","article-title":"Transcriptional Repressor BCL11A in Erythroid Cells","volume":"1459","author":"Zheng","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omtn.2026.102859_bib65","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2016-08-736249","article-title":"Strict in vivo specificity of the Bcl11a erythroid enhancer","volume":"128","author":"Smith","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.102859_bib66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib67","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.omtn.2026.102859_bib68","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jtct.2023.12.312","article-title":"AsCas12a Gene Editing of HBG1\/2 Promoters with Edit-301 Results in Early and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia","volume":"30","author":"Frangoul","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.omtn.2026.102859_bib69","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/crispr.2021.0120","article-title":"ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected","volume":"5","author":"Boutin","year":"2022","journal-title":"CRISPR J."},{"key":"10.1016\/j.omtn.2026.102859_bib71","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/crispr.2024.0036","article-title":"Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects","volume":"7","author":"George","year":"2024","journal-title":"CRISPR J."},{"key":"10.1016\/j.omtn.2026.102859_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/03630269.2024.2369534","article-title":"A Review of Gene Therapies for Hemoglobinopathies","volume":"48","author":"Jones-Wonni","year":"2024","journal-title":"Hemoglobin"},{"key":"10.1016\/j.omtn.2026.102859_bib74","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cells12081103","article-title":"CRISPR-Cas System: The Current and Emerging Translational Landscape","volume":"12","author":"Bhokisham","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2026.102859_bib75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2026.102859_bib76","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib77","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/hematology.2023000487","article-title":"Gene therapy for sickle cell disease","volume":"2023","author":"Leonard","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.omtn.2026.102859_bib78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.medj.2022.03.007","article-title":"Quantity versus quality: Keys to adoptive cell therapy success in breast cancer","volume":"3","author":"Lou","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.omtn.2026.102859_bib79","article-title":"333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program","volume":"8","author":"Palmer","year":"2020","journal-title":"BMJ Specialist Journals"},{"key":"10.1016\/j.omtn.2026.102859_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230047","article-title":"CAR-T-cell products in solid tumors: Progress, challenges, and strategies","volume":"2","author":"Qian","year":"2024","journal-title":"Interdisciplinary Medicine"},{"key":"10.1016\/j.omtn.2026.102859_bib81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41181-023-00194-3","article-title":"Site-specific (68)Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models","volume":"8","author":"Dewulf","year":"2023","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.omtn.2026.102859_bib82","doi-asserted-by":"crossref","first-page":"ND02","DOI":"10.1158\/1538-7445.AM2023-ND02","article-title":"Abstract ND02: CTX112 and CTX131: Next-generation CRISPR\/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors","volume":"83","author":"Terrett","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.102859_bib83","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/hum.2023.29234.bfs","article-title":"Graphite Bio Pauses Lead Gene Editing Program in Sickle Cell Disease","volume":"34","author":"Philippidis","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000968000.61396.5e","article-title":"S272: safety and efficacy of RM-001 in patients with transfusion-dependent \u0392-thalassemia: early results from the ongoing of autologous HBG1\/2 promoter-modified CD34+ hematopoietic stem and progenitor cells","volume":"7","author":"Liu","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.omtn.2026.102859_bib85","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib86","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13046-024-02993-1","article-title":"GMP-manufactured CRISPR\/Cas9 technology as an advantageous tool to support cancer immunotherapy","volume":"43","author":"Caforio","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.102859_bib87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.pmbts.2021.01.025","article-title":"Genome editing approaches to beta-hemoglobinopathies","volume":"182","author":"Brusson","year":"2021","journal-title":"Progress in molecular biology and translational science"},{"key":"10.1016\/j.omtn.2026.102859_bib88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities","volume":"112","author":"Ho","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omtn.2026.102859_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1292452","article-title":"Current trends of clinical trials involving CRISPR\/Cas systems","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib90","doi-asserted-by":"crossref","first-page":"v36","DOI":"10.1093\/annonc\/mdy151.129","article-title":"A phase I\/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies-Trial in progress","volume":"29","author":"Wei","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2026.102859_bib91","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/13543784.2022.2152323","article-title":"Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFbeta and PD-1\/PD-L1","volume":"31","author":"Quach","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.omtn.2026.102859_bib92","first-page":"A314","article-title":"274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency","volume":"11","author":"Kalaitzidis","year":"2023","journal-title":"BMJ Specialist Journals"},{"key":"10.1016\/j.omtn.2026.102859_bib93","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","article-title":"CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)\/beta(0) transfusion-dependent beta-thalassemia","volume":"28","author":"Fu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib94","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.hoc.2022.03.008","article-title":"Gene Therapy for Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease","volume":"36","author":"Leonard","year":"2022","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.omtn.2026.102859_bib95","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79014","article-title":"Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial","volume":"11","author":"Wang","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2026.102859_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.942325","article-title":"CRISPR\/Cas systems: Delivery and application in gene therapy","volume":"10","author":"Huang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102859_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113891","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment","volume":"176","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.102859_bib98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/10815589231191811","article-title":"Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19","volume":"72","author":"Acharya","year":"2024","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib99","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14728214.2024.2379260","article-title":"Current and emerging drug treatment strategies to tackle sickle cell anemia","volume":"29","author":"Persaud","year":"2024","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.omtn.2026.102859_bib100","first-page":"197","article-title":"CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges","volume":"1866","author":"Yi","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2026.102859_bib101","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/cancers14040947","article-title":"Current Status of CRISPR\/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges","volume":"14","author":"Rafii","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omtn.2026.102859_bib102","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2018.03.010","article-title":"Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy","volume":"423","author":"Mirzaei","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2026.102859_bib103","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Brauer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102859_bib104","first-page":"778","article-title":"Cardiomyopathy: an overview","volume":"79","author":"Wexler","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.omtn.2026.102859_bib105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib106","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1056\/NEJMoa2405734","article-title":"CRISPR-Based Therapy for Hereditary Angioedema","volume":"392","author":"Cohn","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib107","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103100","article-title":"Can biotechnology lead the way toward a sustainable pharmaceutical industry?","volume":"87","author":"Etit","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102859_bib109","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/op500023q","article-title":"Precompetitive collaboration on enabling technologies for the pharmaceutical industry","volume":"18","author":"Welch","year":"2014","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.omtn.2026.102859_bib110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eng.2023.09.005","article-title":"First CRISPR-Based Therapy Poised to Reach Patients","volume":"30","author":"Welsh","year":"2023","journal-title":"Engineering"},{"key":"10.1016\/j.omtn.2026.102859_bib111","first-page":"233","article-title":"Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C","volume":"9","author":"Vieira","year":"2024","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.omtn.2026.102859_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2024.102922","article-title":"Pharmaceutical innovation collaboration, evaluation, and matching","volume":"98","author":"Liu","year":"2024","journal-title":"J. Health Econ."},{"key":"10.1016\/j.omtn.2026.102859_bib113","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.arcmed.2020.05.021","article-title":"Extensive Partnership, Collaboration, and Teamwork is Required to Stop the COVID-19 Outbreak","volume":"51","author":"Chakraborty","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.omtn.2026.102859_bib114","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/vaccines11030682","article-title":"SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic","volume":"11","author":"Chakraborty","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2026.102859_bib115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/vaccines9060600","article-title":"Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis","volume":"9","author":"Chakraborty","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2026.102859_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102295","article-title":"The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges","volume":"35","author":"Chakraborty","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102859_bib117","author":"Research"},{"key":"10.1016\/j.omtn.2026.102859_bib118","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMsa1008268","article-title":"The role of public-sector research in the discovery of drugs and vaccines","volume":"364","author":"Stevens","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib119","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omtn.2017.06.005","article-title":"Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102859_bib120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","article-title":"Therapeutic advances of miRNAs: A preclinical and clinical update","volume":"28","author":"Chakraborty","year":"2021","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.omtn.2026.102859_bib121","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/d41586-022-00629-y","article-title":"Major CRISPR patent decision won't end tangled dispute","volume":"603","author":"Ledford","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102859_bib122","author":"Regalado"},{"key":"10.1016\/j.omtn.2026.102859_bib123","first-page":"667","article-title":"CRISPR, Patents, and the Public Health","volume":"90","author":"Sherkow","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib124","series-title":"CRISPRized Horticulture Crops: Genome Modified Plants and Microbes in Food and Agriculture","first-page":"487","article-title":"Global Patent Landscape in CRISPR-Cas","author":"Arif","year":"2024"},{"key":"10.1016\/j.omtn.2026.102859_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.wpi.2021.102038","article-title":"The trends in CRISPR research: a patent and literature study with a focus on India","volume":"65","author":"Roy Chowdhury","year":"2021","journal-title":"World Pat. Inf."},{"key":"10.1016\/j.omtn.2026.102859_bib126","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41587-019-0138-7","article-title":"Worldwide CRISPR patent landscape shows strong geographical biases","volume":"37","author":"Martin-Laffon","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102859_bib127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.pmbts.2021.01.009","article-title":"Patents and technology transfer in CRISPR technology","volume":"180","author":"Grobler","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.omtn.2026.102859_bib129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: Challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2026.102859_bib130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","article-title":"Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges","volume":"15","author":"Luther","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.omtn.2026.102859_bib131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-021-01487-4","article-title":"Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy","volume":"21","author":"Rasul","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2026.102859_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102859_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102859_bib134","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.3390\/ijms21197353","article-title":"Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors","volume":"21","author":"Shalaby","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.102859_bib135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/nat.2019.0790","article-title":"Evaluation and Reduction of CRISPR Off-Target Cleavage Events","volume":"29","author":"Vakulskas","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle Delivery of CRISPR\/Cas9 for Genome Editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2026.102859_bib137","first-page":"21","article-title":"Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing","volume":"18","author":"Asmamaw Mengstie","year":"2024","journal-title":"Biologics."},{"key":"10.1016\/j.omtn.2026.102859_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102859_bib139","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 Protein","volume":"109","author":"Mehta","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omtn.2026.102859_bib140","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1016\/j.ymthe.2025.06.045","article-title":"Peeling back the layers of immunogenicity in Cas9-based genomic medicine","volume":"33","author":"Stigzelius","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102859_bib141","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102859_bib142","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1408","article-title":"Immunity to CRISPR Cas9 and Cas12a therapeutics","volume":"10","author":"Chew","year":"2018","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib143","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics","volume":"4","author":"Liu","year":"2021","journal-title":"Precis. Clin. Med."},{"key":"10.1016\/j.omtn.2026.102859_bib144","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/S0140-6736(23)02797-6","article-title":"The promise of genetic therapies in sickle cell disease","volume":"402","author":"The","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102859_bib145","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102859_bib146","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10529-016-2064-9","article-title":"Improved delivery of Cas9 protein\/gRNA complexes using lipofectamine CRISPRMAX","volume":"38","author":"Yu","year":"2016","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.omtn.2026.102859_bib147","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2019.3048","article-title":"Comparison between Lipofectamine RNAiMAX and GenMute transfection agents in two cellular models of human hepatoma","volume":"63","author":"Berardo","year":"2019","journal-title":"Eur. J. Histochem."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:20:16Z","timestamp":1780104016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":146,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253126000302"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102859","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102859"}}